Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 426115 in Type 2 Diabetes Mellitus
NCT01968265Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Jan 2015
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of GCCR ASO in type 2 diabetes mellitus (T2DM), sponsored by Ionis Pharmaceuticals. Started Oct 2013; status: completed.
02
Drugs
GCCR ASO
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01968265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01968265.